



L S P

Life Sciences Partners

## **Life Sciences Partners III holds first close at € 65 million**

Amsterdam, June 15, 2005

Life Sciences Partners (LSP) today announced the first close of its third fund at € 65 million. LSP III is a venture capital fund dedicated to life science investments in Europe, with a focus on the Benelux and Germany. All major investors of the previous LSP funds committed to LSP III, including, among others, the European Investment Fund, Residex and DSM. The fund also received commitments from a number of new investors in Germany, Switzerland, Luxembourg and Finland. LSP III will invest in 15 to 20 companies active in the life science area in the Benelux, Germany and the rest of Europe, consistent with the strategy of its previous funds. LSP III already has four later stage investments in the portfolio: Octoplus (NL), Jerini (G), Idea AG (G) and Zealand Pharma (DK). These investments all have a short term exit horizon.

“We feel proud of having been able to establish LSP III in the current difficult market environment,” said Martijn Kleijwegt, Managing Partner at LSP. He added: “We are particularly pleased with the new high quality investors participating in LSP III, including SwissRe, Finnish Industry Investment, Proventure and BGL Investment Partners. As a result of the increased interest shown by the new investors in LSP III and the four high potential investments already in the LSP III portfolio, we feel confident of attracting more investors following the first closing.”

Based in Amsterdam and Munich, LSP has successfully invested in the human life sciences for over 15 years. Since inception, LSP’s management has invested in 40 life science companies, of which 13 have successfully completed their IPO or merged with leading companies in the industry.

Specific examples include Rhein Biotech, Qiagen and Crucell. With a strong management team and an extensive scientific and financial network, LSP currently has € 225 million in capital under management. By carefully balancing risks, adding value as a lead investor and taking board responsibility in its portfolio companies, LSP has established itself among the leading life science investors in Europe.